OA-49 Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ) — Thierry Façon (2024) | RDL Network
OA-49 Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)
Thierry Façon, Meletios A Dimopoulos, Xavier Leleu, Meral Beksaç, Luděk Pour, Roman Hájek, Zhuogang Liu, Jiří Minařík, Philippe Moreau, Joanna Romejko‐Jarosińska, Ivan Špıčka, Vladimir Vorobyev, Michèle Cavo, Hartmut Goldschmidt, Thomas G. Martin, Salomon Manier, Marie-France Brégeault, Sandrine Macé, Christelle Berthou, Robert Z. Orlowski
Meletios A Dimopoulos, Xavier P. Leleu, Meral Beksaç, Luděk Pour, Roman Hájek, Zhuogang Liu, Jiří Minařík, Philippe Moreau, Joanna Romejko‐Jarosińska, Ivan Spicka, Vladimir Vorobyev, Elena Zamagni, Hartmut Goldschmidt, Thomas G. Martin, Robert Orlowski, Zandra Klippel, Umer Khan, Sandrine Macé, Helgi van de Velde, Thierry Façon
Salomon Manier, Meletios A Dimopoulos, Xavier Leleu, Philippe Moreau, Michèle Cavo, Hartmut Goldschmidt, Robert Z. Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T. Shafer, Meral Beksaç, Thierry Façon
Salomon Manier, Meletios A Dimopoulos, Xavier P. Leleu, Philippe Moreau, Michèle Cavo, Hartmut Goldschmidt, Robert Z. Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T. Shafer, Meral Beksac, Thierry Façon
Discussion(0)
No comments yet. Be the first to comment.